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Abstract
Objectives: There are no prospective studies of laparoscopic microwave (MW) ablation in patients with
hepatocellular carcinoma (HCC). The aim of this study was to demonstrate the safety and efficacy of
laparoscopic MW ablation.
Methods: A prospective study group of consecutive HCC patients considered ineligible for liver resec-
tion and/or percutaneous ablation was conducted from December 2009 to December 2010. Short-term
(3-month) outcomes included a centralized revision of radiological response, mortality and morbidity.
Mid-term (24-month) outcomes included time to recurrence in the study group compared with that in a
cohort of consecutive patients treated with laparoscopic radiofrequency (RF) ablation using propensity
score analysis.
Results: A total of 42 patients were enrolled. Their median age was 64 years; 67% were positive for
hepatitis C virus; 33% were of Child–Pugh class B status; the median tumour diameter was 2.5 cm, and
48% of patients had multinodular HCC. In 47 of 50 (94%) nodules treated with MW ablation, a complete
radiological response was observed at 3 months. There was no perioperative mortality. The overall
morbidity rate was 24%. The 2-year survival rate was 79% and the 2-year recurrence rate was 55%.
Using propensity score analysis (in 28 MW ablation patients and 28 RF ablation controls), 2-year
recurrence rates were 55% in the MW ablation group and 77% in the control group (P = 0.03).
Conclusions: Laparoscopic MW ablation is a safe and effective therapeutic option for selected HCC
patients who are ineligible for liver resection and/or percutaneous ablation.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer in the world.1
The prognosis in HCC is very poor because of the high degree
of malignancy, high recurrence rates and the impaired liver func-
tion associated with the disease.
Liver transplantation (LT) is the only option able to facilitate
the cure of both the tumour and the underlying chronic liver
disease, but the severe shortage of donor organs greatly limits its
applicability. Surgical resection is considered the treatment of
choice for HCC in patients with and without cirrhosis, provided
that liver function reserve is adequate.2
Unfortunately, the majority of patients (75%) with HCC are
not candidates for resection, firstly because of their poor hepatic
functional reserve, and secondly because advanced tumours, a
tumour location close to major intrahepatic vessels and multi-
focal tumours preclude a negative margin resection.3
Because of the limited applicability of surgical treatment for
HCC, over the past decade non-surgical therapeutic modalities*Other members of the group are listed in the Acknowledgements.
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have been developed, such as transarterial chemoembolization
(TACE), percutaneous ethanol injection (PEI), and percutaneous
radiofrequency (RF) and microwave (MW) ablation.4,5
Although both thermal ablation therapies (RF and MW) have
been widely used for the local treatment of HCC, the differences
between these two techniques have not been clearly demon-
strated.5 Radiofrequency ablation is considered the first option in
the treatment of HCC of ≤2.0 cm, although MW ablation seems
to have some advantages.6,7 In particular, MW ablation potentially
induces tumour necrosis within a shorter period of ablation, does
not result in tissue desiccation or charring and achieves a greater
zone of intra-tumoral thermal injury.6 Randomized controlled
trials and multicentre studies comparing RF and MW ablation
have been performed in recent decades, but no differences in
effects on survival or local recurrence were observed.6,8–10 This,
together with the lower cost and a reduced complexity of use
associated with RF ablation accounts for the prevailing use of this
method until 2009, when a new MW probe was introduced.
Microwave ablation is affected by the phenomenon of ‘back
heating’ and exhibits a teardrop-shaped heating pattern as a result
of both poor control over the power reflected (the portion of MW
power unabsorbed by the tissue and propagating back along the
antenna shaft) and severe losses of power along the antenna
feeding cable. In 2009 a new probe was designed, in which minia-
turized cap-chokes were applied in the MW antenna to minimize
the teardrop-shaped ablation zone and to obtain more defined
areas of necrosis. An integrated cooling system was also added to
prevent the shaft from overheating.11
Although recent evidence shows that MW ablation has a good
safety and efficacy profile for HCC of >2.0 cm,12–15 until now no
prospective studies have evaluated this new technology in com-
parison with RF ablation in a laparoscopy-only setting.
A laparoscopic approach to the ablation of HCC is viable in a
significant proportion of patients who are judged to be unsuitable
for hepatic resection or percutaneous ablation because of
impaired liver function, tumour location or extension, or concur-
rent clinical conditions. Moreover, a laparoscopic approach facili-
tates the treatment of several lesions during the same session,
including with different ablation techniques.10,16
This paper reports a prospective study conducted to assess the
efficacy of laparoscopic MW ablation in patients with HCC who
are ineligible for resection and percutaneous ablation.
Materials and methods
Patients
Consecutive patients with HCC and cirrhosis evaluated at the
Hepatobiliary Surgery and Liver Transplantation Unit at Padua
University Hospital between December 2009 and December 2010
were treated according to a previously described16 algorithm in
which laparoscopic MW ablation was considered as a first-line
therapy for patients with Barcelona Clinic Liver Cancer (BCLC)
class A disease and super-selected patients with BCLC class B
disease who were judged ineligible for liver resection and/or per-
cutaneous ablation as a result of negative prognostic factors or
technical contraindications. The selection criteria for laparoscopic
ablation (LA) are described in detail in Table 1. The policy of the
study institution decrees that LT in HCC patients with BCLC class
A or B disease is used only as a second-line or salvage therapy.17,18
In all of the patients enrolled, the diagnosis of HCC was based
on American Association for the Study of Liver Diseases (AASLD)
radiological criteria19,20 or histology.
Patients were told about the innovative nature of the procedure
and were required to provide informed consent in order to be
included in the study.According to the observational nature of the
study and local guidelines, formal approval of the study protocol
by the institutional review board was not required.
All patients underwent a careful preoperative workup, which
included defining the underlying disease according to Child–Pugh
criteria, Model of End-stage Liver Disease (MELD) score, and
morphological study of the tumour using computed tomography
(CT) and/or magnetic resonance imaging (MRI).
Table 1 Selection criteria for laparoscopic microwave ablation in
hepatocellular carcinoma (HCC) patients at Padua University
Hospital
Inclusion criteria Patients, n (%)
Ineligibility for liver resection
• Major resection in BCLC A2-A3-A4 diseasea 18 (43%)
• Technical contraindications 9 (20%)
• Major resection in patients with MELD score of
>10a
15 (37%)
Ineligibility for percutaneous ablation
• Critical location (proximity to GI tract or bladder
or major hepatic vessels; superficial or exophytic
nodules)
29 (69%)
• Untreatable ascites 4 (11%)
• Severe coagulopathy (PT of <40% and/or platelet
count of <30 × 109/l)
9 (20%)
Exclusion criteria
Severe liver decompensation
• MELD score of >20 0
• Child–Pugh class Cb 0
Large multinodular HCC
• Nodule size of >7.0 cm 0
• Number of nodules >5 0
aAmerican Association for the Study of Liver Diseases criteria for liver
resection were generally followed when tumour location or extension
required a major hepatectomy (resection of more than two liver seg-
ments). In selected cases major liver resection was performed in HCC
patients who did fulfil guidelines using technical expedients such as a
portocaval shunt. The same strategy was followed for patients with
MELD scores of >10.
bIn selected HCC patients with Child–Pugh class C cirrhosis waiting for
liver transplantation, laparoscopic ablation was considered as bridging
therapy: these patients were not included in this study.
BCLC, Barcelona Clinic Liver Cancer; MELD, Model for End-stage Liver
Disease; GI, gastrointestinal; PT, prothrombin time.
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Surgical procedure and postoperative follow-up
Procedures were performed with the patient in a supine position
in all cases. The open approach (Hasson’s technique) was used to
obtain a pneumoperitoneum and inflation pressure was main-
tained at 8–12 mmHg.A second trocar was inserted in the right or
left upper quadrant (for right or left liver lesions, respectively, and
according to liver anatomy) to allow the passage of the ultrasound
probe. After the peritoneal cavity had been explored, laparoscopic
intraoperative ultrasound was performed to complete the disease
staging, confirm the location of the tumour and establish its rela-
tionship with the major hepatic vasculature.
The ablation technique adopted in the study group was MW
ablation (AMICA; HS Hospital Service SpA, Aprilia, Italy). In the
retrospective control group, RF ablation was used (Cool-tip RF;
Valleylab-Tyco Healthcare Group, Boulder, CO, USA).
Microwave and RF ablation were mandatory only for nodules
of >1.0 cm. Nodules of <1.0 cm detected during laparoscopic
ultrasound could be treated by alcohol injection (5–20 ml)
according to the surgeon’s decision.
Ablation needles were inserted percutaneously and placed
inside the lesion under laparoscopic ultrasound guidance. A small
tubular drain was then inserted to be removed postoperatively.
The local efficacy of ablation at the study institution was evalu-
ated with CT and/orMRI in all patients at 20–40 days after LA and
at 3 months following modified RECIST (response evaluation
criteria in solid tumours) recommendations.19,20 All radiological
examinations were submitted to centralized radiological revision
by one expert radiologist and fulfilled specific technical require-
ments: multi-slice CT scanners (typically of 8–64 detectors) were
used for dynamic acquisition in the three phases for the study of
hepatic parenchyma (arterial, portal, equilibrium) after an infu-
sion of iodinated contrast media of 320–400 mg/ml at a rate of
2–4 ml/s, using a bolus tracking technique.
Magnetic resonance imaging scans were obtained as multi-
planar T2-weighted, T2-weighted with fat saturation,
T1-weighted out of phase and in phase acquisitions after injection
of paramagnetic contrast agent (0.1–0.2 mmol/kg at 2 ml/s)
during exposure to a highly magnetic field (1.0–1.5 TESLA).
In the case of complete ablation, an enhanced follow-up proto-
col consisting of CT and/or MRI repeated every 3 months for the
first year and every 6 months thereafter was followed.
Incomplete ablation or local recurrences were treated according
to the study institution’s treatment algorithm.16 In this context,
the more common therapies were a repeat LA procedure, TACE
and LT.
Study design
The objective of this study was to evaluate the efficacy and safety
of laparoscopic MW ablation in HCC patients who were judged to
be unsuitable for liver resection or percutaneous ablation, but
who fulfilled the study inclusion criteria (Table 1).
The primary endpoint was the number of patients free of local
tumour persistence or progression [partial, stable or progressive
disease according to modified RECIST (mRECIST) criteria]
assessed at 3 months after the procedure. Secondary endpoints
were: postoperative mortality and morbidity; recurrence rate at
24 months, and patient survival at 24 months.
The planned enrolment period was 12 months. The minimal
follow-up required in each enrolled patient was 24 months.
This study was designed as a classical one-stage Phase II trial
with the following assumptions: the hypotheses of interest were
H0 = r ≤ 50% against HA: r ≥ 75%, where r is the proportion of
patients free of local progression at 3 months after the procedure;
the type I error rate was set at 5%, and the type II error rate was set
at 10%.
Under these assumptions, a minimum of 33 patients were
required. The evaluation of treatment efficacy was based on the
number of patients free of local progression at 3 months after the
procedure: if this number was at most 21, the treatment would be
declared insufficiently effective; if this number amounted to 22 or
more, the treatment would be declared sufficiently effective.
Patients who were lost from follow-up within 3 months were to be
replaced in order to ensure that 33 patients were evaluable at
3 months.
A total of 100 consecutive HCC patients treated with
laparoscopic RF ablation during the period 2004–2009 were
selected from the study institution’s prospective HCC database
using the same criteria described in Table 1. These patients were
used to represent an historical control group to test the mid-term
efficacy of laparoscopic MW ablation (recurrence rate and patient
survival at 24 months). In order to limit selection bias in this
retrospective cohort, the first 30 cases of LA performed at the
study institution were excluded and a propensity score analysis
was performed.
Statistical analysis
Values for continuous variables are presented as medians (ranges).
Values for categorical-nominal variables are presented as frequen-
cies (%). For subgroup comparisons, quantitative variables were
compared using Student’s t-test or the Wilcoxon rank sum test,
and categorical variables were compared using the chi-squared or
Fisher’s exact test, as appropriate.
The length of the follow-up after LA was calculated from the
date of the operation to the date of HCC recurrence (for time-to-
recurrence analysis) or the patient’s death (for survival analysis)
or the latest follow-up. For both recurrence and survival analysis,
LT represented a censor point. The last follow-up date considered
was 15 March 2013. The length of follow-up and survival were
expressed as the median (range).
Time-to-recurrence and overall survival curves were calculated
using the Kaplan–Meier technique and compared with the log-
rank test.
To overcome biases arising from the different distributions of
covariates among patients undergoing MW ablation and those
undergoing RF ablation, a one-to-one match was created using
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propensity score analysis.21 Given the matched nature of the
analysis, differences in continuous baseline variables were assessed
using the paired t-test.
A P-value of <0.05 was considered to indicate statistical
significance.
All statistical calculations were performed using jmpVersion 9.0
2010 (SAS Institute, Inc., Cary, NC, USA).
Results
Patient characteristics
Laparoscopic ablation was prospectively applied in 42 consecutive
HCC patients between December 2009 and December 2010. The
characteristics of these patients are shown in Table 2. The median
patient age was 64 years and the sample showed a male predomi-
nance. The main aetiology of cirrhosis was hepatitis C virus infec-
tion (67%), followed by alcohol abuse (28%). The median MELD
score was 10 and 33% of patients were of Child–Pugh class
B status.
Only 10 patients (24%) had very early-stage HCC,whereas nine
(21%) demonstrated BCLC stage B disease. The reasons why
patients were considered ineligible for resection and percutaneous
ablation are depicted in Table 1.
A total of 72 nodules were treated during the laparoscopic
procedure in the 42 enrolled patients: 50 of these nodules were
ablated using MW devices, and 22 nodules that were <1.0 cm in
size underwent alcohol injection as established by the study
protocol.
Short-term analysis
Blood transfusions were given to two patients (5%). The conver-
sion rate during LA was 0%.
There was no perioperative mortality. The overall morbidity
rate was 24% (Table S1, online). The most common postoperative
complication was fever, which occurred in five patients (12%).
The median postoperative hospital stay was 3 days (range:
1–8 days).
Imaging studies at 3 months showed incomplete ablation in
only three (6%) of the 50 nodules (Table S2, online). Complete
ablation was achieved in 100% of nodules of <3.0 cm and in 80%
of those of >3.0 cm in size (Tables S3 and S4, online).
In a patient-by-patient analysis, 37 patients (88%) were found
to be free of local recurrence at 3 months, a finding that marked
the achievement of the primary endpoint of the study.
Mid-term analysis
The characteristics of the prospective cohort of 42 patients treated
with MW ablation were compared with those of a retrospective
cohort of 100 consecutive patients submitted to RF ablation
during 2004–2009. The two study populations were extremely
similar (Table 3) because the same selection criteria for LA were
applied in both (Table 1).
Nevertheless, significant differences between the study and
control groups in the aetiology of underlying liver disease and in
α-fetoprotein values were found (Table 3).
When a 24-month follow-up period was applied in both the
(unmatched) cohorts, 2-year survival rates were 81% and 59%,
respectively, in the MW and RF groups (P = 0.0089) (Fig. 1).
Two-year recurrence rates were 55% in MW patients and 74%
in RF patients (P = 0.0162) (Fig. 2).
To simulate a randomized clinical trial involving two compa-
rable cohorts of patients, a propensity score analysis was per-
formed. This method provided two subgroups of 28 patients each
without significant differences in the covariates analysed
(Table 3).
The two matched cohorts demonstrated similar rates of sur-
vival (P = 0.2056) (Fig. 3). Conversely, MW patients maintained a
better recurrence profile than those submitted to RF ablation:
2-year recurrence rates were 55% and 77% in the MW and RF
groups, respectively (P = 0.0354) (Fig. 4).
Table 2 Demographic data for 42 patients with hepatocellular carci-
noma (HCC) and liver cirrhosis undergoing laparoscopic microwave
ablation
Variables
Female sex, n (%) 7 (17%)
Age, years, median (range) 64 (47–81)
Aetiology of liver cirrhosis, n (%)
HCV-related 28 (67%)
HBV-related 2 (5%)
Alcohol-related 12 (28%)
Liver function, n (%)
Child–Pugh class A 28 (67%)
Child–Pugh class B 14 (33%)
Child–Pugh class C 0
MELD score, median (range) 10 (6–16)
α-fetoprotein, ng/ml, median (range) 7 (2–775)
Largest nodule diameter, mm, median (range) 25 (15–53)
Number of nodules, n (%)
1 22 (52%)
2 or 3 18 (43%)
>3 2 (5%)
BCLC stage B disease, n (%) 9 (21%)
Number of treated nodules, n (%)
1 34 (81%)
2 8 (19%)
Nodule location, n (%)
Left lobe (segments I–IV) 8 (19%)
Right lobe (segments V–VIII) 29 (69%)
Both 5 (12%)
HCV, hepatitis C virus; HBV, hepatitis B virus; MELD, Model for End-
stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer.
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Discussion
AlthoughMW ablation theoretically has greater potential ablation
power than RF ablation, there are no studies demonstrating the
superiority of MW over RF ablation.6,8,10
This is the first prospective study to evaluate the safety and
efficacy of the newMW setting in a laparoscopic-only approach in
HCC patients. Although several recent experiences12–15 have dem-
onstrated the safety and efficacy of MW ablation in larger
numbers of patients, these series were retrospective, often consid-
ered other liver tumours in addition to HCC, did not focus on a
laparoscopic approach, and reported incomplete data, or non-
uniform selection criteria or follow-up schedules, as is typical of
retrospective studies.
Table 3 Comparisons between patients with hepatocellular carcinoma undergoing laparoscopic microwave (MW) ablation and those
undergoing laparoscopic radiofrequency (RF) ablation (unmatched and matched cohorts)
Variables MW ablation
unmatched
patients
(n = 42)
RF ablation
unmatched
patients
(n = 100)
MW ablation
matched
patients
(n = 28)
RF ablation
matched
patients
(n = 28)
Female sex, n (%) 7 (17%) 17 (17%) 5 (18%) 6 (21%)
Age, years, median (range) 64 (47–81) 63 (34–81) 64 (47–80) 64 (34–80)
Aetiology of liver cirrhosis, n (%)
HCV-related 28 (67%) 39 (39%)a 16 (57%) 16 (57%)
HBV-related 2 (5%) 28 (28%)a 2 (7%) 2 (7%)
Alcohol-related 12 (29%) 40 (40%) 10 (36%) 10 (36%)
Child–Pugh score, median (range) 6 (5–9) 6 (5–9) 6 (5–8) 6 (5–9)
MELD score, median (range) 10 (6–16) 10 (6–19) 11 (6–16) 10 (7–19)
α-fetoprotein, ng/ml, median (range) 7 (2–775) 44 (1–28356)b 9 (2–775) 8 (1–148)
Largest nodule diameter, mm, median (range) 25 (15–53) 30 (10–60) 25 (15–53) 27 (12–60)
Number of nodules, n (%)
1 22 (52%) 54 (54%) 12 (43%) 15 (54%)
2 or 3 18 (43%) 39 (39%) 15 (54%) 12 (43%)
>3 2 (5%) 7 (7%) 1 (3%) 1 (3%)
BCLC stage B disease, n (%) 9 (21%) 29 (29%) 7 (25%) 7 (25%)
aP < 0.05;
bP < 0.1.
HCV, hepatitis C virus; HBV, hepatitis B virus; MELD, Model for End-stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer.
Figure 1 Kaplan–Meier curves showing survival in unmatched
cohorts of hepatocellular carcinoma patients submitted to
laparoscopic microwave (MW) or radiofrequency (RF) ablation (log-
rank test, P = 0.0089)
Figure 2 Kaplan–Meier curves showing recurrence in unmatched
cohorts of hepatocellular carcinoma patients submitted to
laparoscopic microwave (MW) or radiofrequency (RF) ablation (log-
rank test, P = 0.0162)
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This study was designed in 2009 to evaluate short-term out-
comes in patients undergoing laparoscopic MW ablation. The
laparoscopic approach was already in frequent use at the study
institution16 and represented the ideal setting in which to test this
new MW technology because it has greater intrinsic ability to
avoid the occurrence of side-effects such as bleeding or damage to
extrahepatic organs that are close to the HCC. In the 12-month
enrolment period, the number of patients recruited (n = 42)
exceeded that required according to sample size calculations
(n = 33).
This study is supported by its substantial recruitment numbers
and the fact that its primary endpoint was achieved.
The present results broadly overlap with those of other study
groups that have used laparoscopic RF ablation, particularly with
reference to the safety of the procedure: the present study found
no perioperative mortality and a low incidence of specific mor-
bidity (24%), both of which are comparable with findings
elsewhere.22–25 The surgical conversion rate in the present study
(0%) is also in line with rates reported in the literature.26
The median postoperative hospital stay in the present study
was also relatively short (3 days) and similar to those reported
elsewhere.4,10,27,28
In other experiences,23 however, LA was used in patients who
were eligible for traditional treatments and who were selected
according to the numbers and sizes of nodules and the severity of
cirrhosis. The present study’s enrolment criteria were particular in
that LA was applied prospectively to super-selected patients who
were considered unresectable or ineligible for percutaneous abla-
tion16 (Table 1).
This particular feature of the treatment algorithm used in the
present study derives from a hierarchy of therapeutic options, in
which a potentially radical therapy can be assigned regardless of
BCLC stage29 whenever possible: the first option is to consider
liver resection or percutaneous ablation; the second is to consider
LA in patients in whom resection or percutaneous ablation are
technically infeasible, and TACE and sorafenib are considered in
patients in whom the previous options have been judged infeasi-
ble according to tumour stage (Table 1).
Because of the shortage of organs in Italy and the strong epi-
demiological pressure imposed by HCC, LT was considered as the
first-line option only in HCC patients of Child–Pugh class C
status30 or in young patients positive for hepatitis B virus infection
with multinodular HCC, and was considered as second-line
therapy only in patients in whom first-line options had failed for
reasons of recurrence or incomplete treatment.
This enrolment policy enabled the provision of LA as a viable
alternative to resection and/or percutaneous ablation in patients
with BCLC stage A disease, and as a potentially radical therapeutic
alternative to TACE in super-selected patients with BCLC stage B
disease.
The role of LA in the present treatment algorithm is justified by
some of the theoretical advantages afforded by the laparoscopic
approach with respect to percutaneous procedures, which include
the ability to approach lesions adjacent to the gastrointestinal
tract, gallbladder and bile ducts, or in the presence of thrombo-
cytopenia, and the ability to use intraoperative ultrasound to
target lesions more accurately.
Liver function in the present study group is indicated by the
findings that 50% of patients had MELD scores of >10 and 33%
had Child–Pugh class B cirrhosis, both of which reflect the present
study’s particular enrolment criteria. Thus, the 2-year survival
rate of 79% would appear to represent an excellent result.
A recent multicentre Italian study31 described a 40% recurrence
rate in patients with single HCC lesions of <3.0 cm treated with
RF ablation.
Figure 3 Kaplan–Meier curves showing survival in propensity score-
matched cohorts of hepatocellular carcinoma patients submitted to
laparoscopic microwave (MW) or radiofrequency (RF) ablation (log-
rank test, P = 0.2056)
Figure 4 Kaplan–Meier curves showing recurrence in propensity
score-matched cohorts of hepatocellular carcinoma patients sub-
mitted to laparoscopic microwave (MW) or radiofrequency (RF) abla-
tion (log-rank test, P = 0.0354)
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Given that 50% of patients in the present study population had
a largest tumour diameter of >2.5 cm and 48% had multinodular
HCC, the present 2-year recurrence rate of 55% would also seem
to be acceptable.
This consideration is sustained by the present study’s internal
comparison with patients submitted to laparoscopic RF ablation.
This analysis showed a significant advantage of MW ablation over
RF ablation in preventing tumour recurrence at 2 years (Fig. 4)
when patients were matched for tumour characteristics.
Some limitations derive from the retrospective nature of this
comparison. It should be underlined, however, that the learning
curve effect in the LA procedure may be considered negligible in
this study because the first 30 LA treatments performed at the
study institution were excluded from analysis and all of the sur-
geons involved had experience with percutaneous RF ablation of
≥10 years. Moreover, the propensity score approach refined all
other differences between the study and control groups.
In conclusion, laparoscopic MW ablation proved to be a safe
and apparently effective therapy even in patients with moderately
impaired liver function who would be considered as suboptimal
candidates for resection, percutaneous ablation and TACE.32 The
present findings may be justified by patient super-selection and
the favourable physiopathology of minimally invasive approaches;
however, larger prospective studies are required to confirm such
prognostic results in this therapeutic setting.
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Supporting information
Additional supporting information may be found in the online version of this
article at the publisher's website:
Table S1. Complications after laparoscopic microwave ablation in 42 patients
with hepatocellular carcinoma.
Table S2. Radiological efficacy of laparoscopic microwave ablation consid-
ered as the complete absence of contrast enhancement in arterial phase
computed tomography after contrast medium injection.
Table S3. Features of nodules treated with microwave coagulation therapy.
Outcome 1: no contrast enhancement; outcome 2: residual contrast enhance-
ment seen at centralized computed tomography revision.
Table S4. Features of nodules presenting residual contrast enhancement
(nodular pattern) in arterial phase computed tomography.
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